Hacker News: aaavl2821https://news.ycombinator.com/user?id=aaavl2821Hacker News RSShttps://hnrss.org/hnrss v2.1.1Sat, 11 Apr 2026 11:24:02 +0000<![CDATA[Sophistical Refutations]]>Article URL: https://en.wikipedia.org/wiki/Sophistical_Refutations

Comments URL: https://news.ycombinator.com/item?id=45451857

Points: 1

# Comments: 0

]]>Thu, 02 Oct 2025 16:29:13 +0000https://en.wikipedia.org/wiki/Sophistical_Refutationsaaavl2821https://news.ycombinator.com/item?id=45451857https://news.ycombinator.com/item?id=45451857<![CDATA[Sophist]]>Article URL: https://en.wikipedia.org/wiki/Sophist

Comments URL: https://news.ycombinator.com/item?id=45446029

Points: 15

# Comments: 5

]]>Thu, 02 Oct 2025 03:18:12 +0000https://en.wikipedia.org/wiki/Sophistaaavl2821https://news.ycombinator.com/item?id=45446029https://news.ycombinator.com/item?id=45446029<![CDATA[Can AI predict clinical trial outcomes?]]>Article URL: https://www.baybridgebio.com/blog/ai-empowered-analysts/ai-clinical-trial.html

Comments URL: https://news.ycombinator.com/item?id=44261927

Points: 2

# Comments: 0

]]>Thu, 12 Jun 2025 19:14:24 +0000https://www.baybridgebio.com/blog/ai-empowered-analysts/ai-clinical-trial.htmlaaavl2821https://news.ycombinator.com/item?id=44261927https://news.ycombinator.com/item?id=44261927<![CDATA[AI won't replace biotech analysts]]>Article URL: https://www.baybridgebio.com/blog/ai-empowered-analysts/ai-empowered-analysts.html

Comments URL: https://news.ycombinator.com/item?id=44252767

Points: 1

# Comments: 0

]]>Wed, 11 Jun 2025 23:07:21 +0000https://www.baybridgebio.com/blog/ai-empowered-analysts/ai-empowered-analysts.htmlaaavl2821https://news.ycombinator.com/item?id=44252767https://news.ycombinator.com/item?id=44252767<![CDATA[Show HN: Research Pharma Markets with AI]]>Article URL: https://www.baybridgebio.com/drug-revenue.html

Comments URL: https://news.ycombinator.com/item?id=43497545

Points: 2

# Comments: 0

]]>Thu, 27 Mar 2025 20:02:44 +0000https://www.baybridgebio.com/drug-revenue.htmlaaavl2821https://news.ycombinator.com/item?id=43497545https://news.ycombinator.com/item?id=43497545<![CDATA[Show HN: Search for drugs approved to treat a given disease]]>Article URL: https://www.baybridgebio.com/drug-revenue.html

Comments URL: https://news.ycombinator.com/item?id=42880073

Points: 1

# Comments: 0

]]>Thu, 30 Jan 2025 17:42:52 +0000https://www.baybridgebio.com/drug-revenue.htmlaaavl2821https://news.ycombinator.com/item?id=42880073https://news.ycombinator.com/item?id=42880073<![CDATA[Better obesity drugs are coming soon]]>Article URL: https://www.baybridgebio.com/blog/obesity-clinical-data.html

Comments URL: https://news.ycombinator.com/item?id=41779180

Points: 2

# Comments: 0

]]>Tue, 08 Oct 2024 16:37:39 +0000https://www.baybridgebio.com/blog/obesity-clinical-data.htmlaaavl2821https://news.ycombinator.com/item?id=41779180https://news.ycombinator.com/item?id=41779180<![CDATA[The Future of the Obesity Market]]>Article URL: https://www.baybridgebio.com/blog/obesity-clinical-data.html

Comments URL: https://news.ycombinator.com/item?id=41732636

Points: 1

# Comments: 0

]]>Thu, 03 Oct 2024 17:07:42 +0000https://www.baybridgebio.com/blog/obesity-clinical-data.htmlaaavl2821https://news.ycombinator.com/item?id=41732636https://news.ycombinator.com/item?id=41732636<![CDATA[The obesity drug landscape in one chart]]>Article URL: https://www.baybridgebio.com/blog/obesity-clinical-data.html

Comments URL: https://news.ycombinator.com/item?id=41258926

Points: 3

# Comments: 0

]]>Thu, 15 Aug 2024 18:21:26 +0000https://www.baybridgebio.com/blog/obesity-clinical-data.htmlaaavl2821https://news.ycombinator.com/item?id=41258926https://news.ycombinator.com/item?id=41258926<![CDATA[A primer on the obesity drug landscape]]>Article URL: https://www.baybridgebio.com/blog/obesity-clinical-data.html

Comments URL: https://news.ycombinator.com/item?id=41238705

Points: 2

# Comments: 0

]]>Tue, 13 Aug 2024 19:20:52 +0000https://www.baybridgebio.com/blog/obesity-clinical-data.htmlaaavl2821https://news.ycombinator.com/item?id=41238705https://news.ycombinator.com/item?id=41238705<![CDATA[AI-enabled biotech startup analysis]]>Article URL: https://www.baybridgebio.com/ai-research.html

Comments URL: https://news.ycombinator.com/item?id=38073643

Points: 1

# Comments: 0

]]>Mon, 30 Oct 2023 18:30:11 +0000https://www.baybridgebio.com/ai-research.htmlaaavl2821https://news.ycombinator.com/item?id=38073643https://news.ycombinator.com/item?id=38073643<![CDATA[Analyzing gene therapy startup in layman's terms]]>Article URL: https://www.baybridgebio.com/blog/rampart-oct-2023.html

Comments URL: https://news.ycombinator.com/item?id=38034354

Points: 1

# Comments: 0

]]>Fri, 27 Oct 2023 03:20:38 +0000https://www.baybridgebio.com/blog/rampart-oct-2023.htmlaaavl2821https://news.ycombinator.com/item?id=38034354https://news.ycombinator.com/item?id=38034354<![CDATA[AI Analysis of Biotech Startups]]>Article URL: https://www.baybridgebio.com/blog/agomab-oct-2023.html

Comments URL: https://news.ycombinator.com/item?id=37961323

Points: 2

# Comments: 0

]]>Fri, 20 Oct 2023 20:48:05 +0000https://www.baybridgebio.com/blog/agomab-oct-2023.htmlaaavl2821https://news.ycombinator.com/item?id=37961323https://news.ycombinator.com/item?id=37961323<![CDATA[AI investment analyst: initiating coverage on Neumora Therapeutics]]>Article URL: https://www.baybridgebio.com/blog/nmra-initiation.html

Comments URL: https://news.ycombinator.com/item?id=37782115

Points: 1

# Comments: 0

]]>Thu, 05 Oct 2023 18:22:36 +0000https://www.baybridgebio.com/blog/nmra-initiation.htmlaaavl2821https://news.ycombinator.com/item?id=37782115https://news.ycombinator.com/item?id=37782115<![CDATA[Quantifying risk / reward in biotech investing]]>Article URL: https://www.baybridgebio.com/monte-carlo-biotech.html

Comments URL: https://news.ycombinator.com/item?id=37678086

Points: 1

# Comments: 0

]]>Wed, 27 Sep 2023 17:30:32 +0000https://www.baybridgebio.com/monte-carlo-biotech.htmlaaavl2821https://news.ycombinator.com/item?id=37678086https://news.ycombinator.com/item?id=37678086<![CDATA[Valuing Biotech Licensing Deals]]>Article URL: https://www.baybridgebio.com/biotech-licensing.html

Comments URL: https://news.ycombinator.com/item?id=36670159

Points: 1

# Comments: 0

]]>Mon, 10 Jul 2023 17:50:19 +0000https://www.baybridgebio.com/biotech-licensing.htmlaaavl2821https://news.ycombinator.com/item?id=36670159https://news.ycombinator.com/item?id=36670159<![CDATA[Show HN: Value Biotech Licensing Deals]]>Article URL: https://www.baybridgebio.com/biotech-licensing.html

Comments URL: https://news.ycombinator.com/item?id=36620424

Points: 2

# Comments: 0

]]>Thu, 06 Jul 2023 18:16:20 +0000https://www.baybridgebio.com/biotech-licensing.htmlaaavl2821https://news.ycombinator.com/item?id=36620424https://news.ycombinator.com/item?id=36620424<![CDATA[Which VCs are still investing in biopharma?]]>Article URL: https://www.baybridgebio.com/blog/top-100-biotech-vcs.html

Comments URL: https://news.ycombinator.com/item?id=35822349

Points: 1

# Comments: 0

]]>Thu, 04 May 2023 21:30:44 +0000https://www.baybridgebio.com/blog/top-100-biotech-vcs.htmlaaavl2821https://news.ycombinator.com/item?id=35822349https://news.ycombinator.com/item?id=35822349<![CDATA[Biotech VC on pace for worst year since 2016]]>Article URL: https://www.baybridgebio.com/blog/top_vcs_2018.html

Comments URL: https://news.ycombinator.com/item?id=35821842

Points: 2

# Comments: 0

]]>Thu, 04 May 2023 20:48:38 +0000https://www.baybridgebio.com/blog/top_vcs_2018.htmlaaavl2821https://news.ycombinator.com/item?id=35821842https://news.ycombinator.com/item?id=35821842<![CDATA[The biotech venture capital crunch]]>Article URL: https://www.baybridgebio.com/blog/biotech-vc-crunch.html

Comments URL: https://news.ycombinator.com/item?id=35544826

Points: 1

# Comments: 0

]]>Wed, 12 Apr 2023 18:50:58 +0000https://www.baybridgebio.com/blog/biotech-vc-crunch.htmlaaavl2821https://news.ycombinator.com/item?id=35544826https://news.ycombinator.com/item?id=35544826